Anthony M Dart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7832083/publications.pdf

Version: 2024-02-01

218 papers 13,708 citations

18436 62 h-index 24179 110 g-index

257 all docs

257 docs citations

times ranked

257

15708 citing authors

#	Article	IF	CITATIONS
1	An Effective Protocol for Management of International Arrivals at Risk in COVID-19 Pandemic: Experience From the Pre-Hospital Covid-19 Response Teams at Xi'an, China. Frontiers in Public Health, 2022, 10, 753640.	1.3	O
2	Effect of different initial anticoagulant strategies on shortâ€term outcome of patients with symptomatic DVT in China. International Journal of Clinical Practice, 2021, 75, e14619.	0.8	0
3	The Baker Biobank: Understanding Cardiovascular Outcomes. Heart Lung and Circulation, 2020, 29, 1071-1077.	0.2	3
4	Preoperative biomarker evaluation for the prediction of cardiovascular events after major vascular surgery. Journal of Vascular Surgery, 2019, 70, 1564-1575.	0.6	5
5	Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2019, 73, 2846-2855.	1.2	27
6	Pulse Pressure and Diabetic Eye Disease. Journal of the American Heart Association, 2019, 8, e012491.	1.6	1
7	HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study. PLoS ONE, 2019, 14, e0215620.	1.1	20
8	Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. American Heart Journal, 2019, 212, 134-143.	1.2	21
9	Rapid and safe discharge from the emergency department: A single troponin to exclude acute myocardial infarction. EMA - Emergency Medicine Australasia, 2018, 30, 486-493.	0.5	5
10	Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by \hat{l}^2 (sub>2-adrenoceptor overexpression. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H1169-H1178.	1.5	23
11	The relationship between maternal anxiety and cortisol during pregnancy and birth weight of chinese neonates. BMC Pregnancy and Childbirth, 2018, 18, 265.	0.9	25
12	Heart Rate as a Predictor of Outcome Following Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 1113-1120.	0.7	6
13	Admission macrophage migration inhibitory factor predicts long-term prognosis in patients with ST-elevation myocardial infarction. European Heart Journal Quality of Care & Dinical Outcomes, 2018, 4, 208-219.	1.8	7
14	Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture. Cardiovascular Drugs and Therapy, 2017, 31, 145-156.	1.3	24
15	Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis. Clinical Therapeutics, 2017, 39, 1882-1888.	1.1	21
16	A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease. Frontiers in Pharmacology, 2017, 8, 186.	1.6	100
17	Should pulse pressure influence prescribing?. Australian Prescriber, 2017, 40, 26-29.	0.5	9
18	Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. American Journal of Translational Research (discontinued), 2017, 9, 5063-5073.	0.0	39

#	Article	IF	CITATIONS
19	Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial Ischemia. Journal of the American Heart Association, 2016, 5, .	1.6	11
20	Splenic release of platelets contributes to increased circulating platelet size and inflammation after myocardial infarction. Clinical Science, 2016, 130, 1089-1104.	1.8	20
21	Effects of Maternal Cortisol during Pregnancy on Children's Blood Pressure Responses. Neuroendocrinology, 2016, 103, 282-290.	1.2	3
22	Central aortic pressure. Journal of Hypertension, 2015, 33, 188-189.	0.3	0
23	Lipidomic Profiling in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1511-1518.	0.9	49
24	Central Aortic Reservoir-Wave Analysis Improves Prediction of Cardiovascular Events in Elderly Hypertensives. Hypertension, 2015, 65, 629-635.	1.3	40
25	Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. Journal of Translational Medicine, 2015, 13, 314.	1.8	173
26	Pathological hypertrophy reverses $\langle i \rangle^2 \langle i \rangle \langle sub \rangle^2 \langle sub \rangle$ -adrenergic receptor-induced angiogenesis in mouse heart. Physiological Reports, 2015, 3, e12340.	0.7	4
27	Systemic inflammatory response following acute myocardial infarction. Journal of Geriatric Cardiology, 2015, 12, 305-12.	0.2	138
28	How do we improve peer review for manuscripts from culturally divergent origins?. F1000Research, 2015, 4, 39.	0.8	0
29	Internal relationship between symptomatic venous thromboembolism and risk factors: up-regulation of integrin \hat{l}^21 , \hat{l}^22 and \hat{l}^23 levels. American Journal of Translational Research (discontinued), 2015, 7, 624-31.	0.0	1
30	Immune and inflammatory responses in subjects with stable angina and acute myocardial infarction. Journal of Geriatric Cardiology, 2015, 12, 202-3.	0.2	0
31	C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sexual Health, 2014, 11, 580.	0.4	12
32	Associations between surface markers on blood monocytes and carotid atherosclerosis in HIVâ€positive individuals. Immunology and Cell Biology, 2014, 92, 133-138.	1.0	59
33	Role of MIF in myocardial ischaemia and infarction: insight from recent clinical and experimental findings. Clinical Science, 2014, 127, 149-161.	1.8	45
34	Estimation of central aortic blood pressure. Journal of Hypertension, 2014, 32, 1727-1740.	0.3	73
35	Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. Journal of Molecular and Cellular Cardiology, 2014, 69, 32-42.	0.9	52
36	Diverse Regulation of Cardiac Expression of Relaxin Receptor by $\hat{l}\pm 1$ - and \hat{l}^21 -Adrenoceptors. Cardiovascular Drugs and Therapy, 2014, 28, 221-228.	1.3	17

#	Article	IF	CITATIONS
37	Three-dimensional numerical simulation of blood flow in mouse aortic arch around atherosclerotic plaques. Applied Mathematical Modelling, 2014, 38, 4175-4185.	2.2	25
38	The effect of HIV infection on atherosclerosis and lipoprotein metabolism: A one year prospective study. Atherosclerosis, 2013, 229, 206-211.	0.4	31
39	Macrophage Migration Inhibitory Factor for the Early Prediction of Infarct Size. Journal of the American Heart Association, 2013, 2, e000226.	1.6	49
40	Associations Between Fibrocytes and Postcontrast Myocardial T ₁ Times in Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2013, 2, e000270.	1.6	22
41	Endothelial dysfunction in patients with type 2 diabetes post acute coronary syndrome. Diabetes and Vascular Disease Research, 2013, 10, 368-374.	0.9	12
42	Misclassification of studies in â€~Brachial artery tonometry and the Popeye phenomenon'. Journal of Hypertension, 2013, 31, 208.	0.3	1
43	Increased Carotid Intima-Media Thickness and Reduced Distensibility in Human Class III Obesity: Independent and Differential Influences of Adiposity and Blood Pressure on the Vasculature. PLoS ONE, 2013, 8, e53972.	1.1	10
44	Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells. PLoS ONE, 2013, 8, e76206.	1.1	51
45	Effect of Iron Chelation on Myocardial Infarct Size and Oxidative Stress in ST-Elevation–Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 270-278.	1.4	81
46	Effect of altering dietary <i>n</i> -6: <i>n</i> -3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. British Journal of Nutrition, 2012, 108, 1280-1285.	1.2	24
47	Decreased fibrocyte number is associated with atherosclerotic plaque instability in man. Cardiovascular Research, 2012, 95, 124-133.	1.8	15
48	Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiological Genomics, 2012, 44, 211-219.	1.0	83
49	Acute Left Ventricular Remodeling Following Myocardial Infarction. JACC: Cardiovascular Imaging, 2012, 5, 884-893.	2.3	97
50	Usefulness of Transient and Persistent No Reflow to Predict Adverse Clinical Outcomes Following Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 109, 478-485.	0.7	57
51	Impact of Periprocedural Atrial Fibrillation on Short-Term Clinical Outcomes Following Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 109, 471-477.	0.7	38
52	Post-infarct cardiac rupture: Recent insights on pathogenesis and therapeutic interventions., 2012, 134, 156-179.		86
53	Antiâ€inflammatory treatment in patients after percutaneous coronary intervention: another potential use for berberine?. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 404-405.	0.9	3
54	Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice. World Journal of Experimental Medicine, 2012, 2, 30.	0.9	128

#	Article	IF	CITATIONS
55	Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia–reperfusion injury: A predominant role of anti-inflammation. Journal of Molecular and Cellular Cardiology, 2011, 50, 991-999.	0.9	99
56	Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. Thrombosis and Haemostasis, 2011, 105, 356-364.	1.8	19
57	Arterial remodelling following pressure overload by aortic constriction: an overlooked and potentially fertile research area. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 559-561.	0.9	1
58	Myocardial oxidative stress contributes to transgenic β ₂ â€adrenoceptor activationâ€induced cardiomyopathy and heart failure. British Journal of Pharmacology, 2011, 162, 1012-1028.	2.7	99
59	Management of the no-reflow phenomenon. , 2011, 132, 72-85.		27
60	Novel Role of Platelets in Mediating Inflammatory Responses and Ventricular Rupture or Remodeling Following Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 834-841.	1.1	101
61	Plasma Lipidomic Analysis of Stable and Unstable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2723-2732.	1.1	265
62	Vascular stiffness and aging in HIV. Sexual Health, 2011, 8, 474.	0.4	8
63	Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clinical Science, 2010, 119, 175-183.	1.8	21
64	Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. HIV Therapy, 2010, 4, 675-692.	0.6	4
65	Relaxin Therapy Reverses Large Artery Remodeling and Improves Arterial Compliance in Senescent Spontaneously Hypertensive Rats. Hypertension, 2010, 55, 1260-1266.	1.3	61
66	Determinants of Raised Pulse Pressure in Women. Journal of the American College of Cardiology, 2010, 55, 1279.	1.2	0
67	Infarct size and post-infarct inflammation determine the risk of cardiac rupture in mice. International Journal of Cardiology, 2010, 143, 20-28.	0.8	48
68	Cardiovascular effects of relaxin: from basic science to clinical therapy. Nature Reviews Cardiology, 2010, 7, 48-58.	6.1	153
69	c-Jun NH2-Terminal Kinase Activity in Subcutaneous Adipose Tissue but Not Nuclear Factor-κB Activity in Peripheral Blood Mononuclear Cells Is an Independent Determinant of Insulin Resistance in Healthy Individuals. Diabetes, 2009, 58, 1259-1265.	0.3	34
70	Reversal of Cardiac Fibrosis and Related Dysfunction by Relaxin. Annals of the New York Academy of Sciences, 2009, 1160, 278-284.	1.8	24
71	Selective activation of the "b―splice variant of phospholipase Cβ1 in chronically dilated human and mouse atria. Journal of Molecular and Cellular Cardiology, 2009, 47, 676-683.	0.9	29
72	The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. American Heart Journal, 2009, 157, 899-907.	1.2	35

#	Article	IF	CITATIONS
73	The COACH Program Produces Sustained Improvements in Cardiovascular Risk Factors and Adherence to Recommended Medications—Two Years Follow-up. Heart Lung and Circulation, 2009, 18, 388-392.	0.2	37
74	Compliance mismatch between stenotic and distal reference segment is associated with coronary artery disease instability. Atherosclerosis, 2009, 206, 179-185.	0.4	9
75	Antiretroviral compounds and cholesterol efflux from macrophages. Atherosclerosis, 2009, 206, 439-443.	0.4	6
76	Reduced Phosphoinositide 3-Kinase (p $110\hat{l}_{\pm}$) Activation Increases the Susceptibility to Atrial Fibrillation. American Journal of Pathology, 2009, 175, 998-1009.	1.9	151
77	HIV, atherosclerosis and inflammation: implications for treatment. Journal of HIV Therapy, 2009, 14, 61-8.	0.6	8
78	Infusion of Reconstituted HDL leads to Acute Changes in Human Atherosclerotic Plaque In Vivo. Heart Lung and Circulation, 2008, 17, S18.	0.2	0
79	Predictors and Outcomes of the No-Reflow Phenomenon. Heart Lung and Circulation, 2008, 17, S176.	0.2	2
80	Hemodynamic Characteristics Underlying Post-Infarct Cardiac Rupture. Heart Lung and Circulation, 2008, 17, S225-S226.	0.2	0
81	Increased MMP-9 Expression and Secretion by Circulating Mononuclear Cells in Patients with Acute Myocardial Infarction. Heart Lung and Circulation, 2008, 17, S226.	0.2	0
82	HIV infection and high density lipoprotein metabolism. Atherosclerosis, 2008, 199, 79-86.	0.4	127
83	Novel cardiac therapies and innocent bystanders. Lancet, The, 2008, 371, 1726-1728.	6.3	3
84	Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque. Circulation Research, 2008, 103, 1084-1091.	2.0	251
85	Smaller Aortic Dimensions Do Not Fully Account for the Greater Pulse Pressure in Elderly Female Hypertensives. Hypertension, 2008, 51, 1129-1134.	1.3	34
86	Endogenous Relaxin Does Not Affect Chronic Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis. Endocrinology, 2008, 149, 476-482.	1.4	38
87	Higher levels of collagen and facilitated healing protect against ventricular rupture following myocardial infarction. Clinical Science, 2008, 115, 99-106.	1.8	19
88	Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. Journal of Hypertension, 2008, 26, 1037-1042.	0.3	41
89	Importance of Aortic Dimensions in Determining Pulse Pressure in Elderly Hypertensives. Asia Pacific Cardiology, 2008, 2, 35.	0.0	0
90	Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study. European Journal of Echocardiography, 2007, 8, 275-283.	2.3	13

#	Article	IF	Citations
91	Similar Effects of Treatment on Central and Brachial Blood Pressures in Older Hypertensive Subjects in the Second Australian National Blood Pressure Trial. Hypertension, 2007, 49, 1242-1247.	1.3	59
92	Response to Effects of Angiotensin-Converting Enzyme Inhibitors on Central Blood Pressure. Hypertension, 2007, 50, .	1.3	0
93	Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. Journal of Molecular and Cellular Cardiology, 2007, 43, 535-544.	0.9	113
94	Down-regulation of mitofusin-2 expression in cardiac hypertrophy in vitro and in vivo. Life Sciences, 2007, 80, 2154-2160.	2.0	113
95	Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary disease. Cardiovascular Research, 2007, 75, 813-820.	1.8	36
96	OPTIMIZING DOSAGE OF KETAMINE AND XYLAZINE IN MURINE ECHOCARDIOGRAPHY. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 499-507.	0.9	93
97	HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism: Clinical and Experimental, 2006, 55, 90-95.	1.5	88
98	Effect of dietary supplementation with \hat{l}^2 casein A1 or A2 on markers of disease development in individuals at high risk of cardiovascular disease. British Journal of Nutrition, 2006, 95, 136-144.	1.2	30
99	Response to Brachial and Central Arterial Pressure. Hypertension, 2006, 48, .	1.3	0
100	Elevated HDL Cholesterol is Functionally Ineffective in Cardiac Transplant Recipients: Evidence for Impaired Reverse Cholesterol Transport. Transplantation, 2006, 81, 361-366.	0.5	28
101	Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. Journal of Hypertension, 2006, 24, 1663-1670.	0.3	142
102	Insulin Resistance and Atherosclerosis. Endocrine Reviews, 2006, 27, 242-259.	8.9	275
103	Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from Macrophages. PLoS Biology, 2006, 4, e365.	2.6	266
104	Transgenic $\hat{l}\pm 1A$ -adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovascular Research, 2006, 71, 735-743.	1.8	63
105	Letter by Dart et al Regarding Article, "Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study― Circulation, 2006, 114, e537; author reply e540-1.	1.6	3
106	Brachial Blood Pressure But Not Carotid Arterial Waveforms Predict Cardiovascular Events in Elderly Female Hypertensives. Hypertension, 2006, 47, 785-790.	1.3	174
107	Evaluation of Differences in Coronary Plaque Mechanical Behavior in Individuals With and Without Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2826-2827.	1.1	6
108	Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype. American Journal of Clinical Nutrition, 2005, 82, 26-31.	2.2	52

#	Article	IF	CITATIONS
109	Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype. American Journal of Clinical Nutrition, 2005, 82, 26-31.	2.2	61
110	Regression of pressure overload-induced left ventricular hypertrophy in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2702-H2707.	1.5	79
111	Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovascular Research, 2005, 65, 469-477.	1.8	156
112	Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands. Current Cardiology Reviews, 2005, 1, 89-102.	0.6	4
113	Responses to neither exogenous nor endogenous endothelin-1 are altered in patients with hypercholesterolemia. Journal of Lipid Research, 2005, 46, 2667-2672.	2.0	2
114	Assessment of central and peripheral arterial stiffnessStudies indicating the need to use a combination of techniques. American Journal of Hypertension, 2005, 18, 249-260.	1.0	123
115	Large Artery Stiffness Is Not Related to Plasma Cholesterol in Older Subjects with Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 962-968.	1.1	41
116	If channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. British Journal of Pharmacology, 2004, 142, 107-112.	2.7	40
117	Large-Artery Stiffness Contributes to the Greater Prevalence of Systolic Hypertension in Elderly Women. Journal of the American Geriatrics Society, 2004, 52, 368-373.	1.3	64
118	Matrix Metalloproteinase-9 Genotype Influences Large Artery Stiffness Through Effects on Aortic Gene and Protein Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1479-1484.	1.1	126
119	Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet, The, 2004, 364, 849-857.	6. 3	468
120	Plasma C-reactive protein, but not protein S, VCAM-1, von Willebrand factor or P-selectin, is associated with endothelium dysfunction in coronary artery disease. Atherosclerosis, 2004, 172, 345-351.	0.4	22
121	Accuracy of automated auscultatory blood pressure measurement during supine exercise and treadmill stress electrocardiogram-testing. Blood Pressure Monitoring, 2004, 9, 269-275.	0.4	54
122	Analysis of the regional pulse wave velocity by Doppler: methodology and reproducibility. Journal of Human Hypertension, 2003, 17, 407-412.	1.0	50
123	Age and the treatment gap in the use of statins. Lancet, The, 2003, 361, 1925-1926.	6.3	8
124	Single session exercise stimulates formation of prel ² 1-HDL in leg muscle. Journal of Lipid Research, 2003, 44, 522-526.	2.0	28
125	Coaching patients On Achieving Cardiovascular Health (COACH). Archives of Internal Medicine, 2003, 163, 2775.	4.3	313
126	Altered calcium transient and development of hypertrophy in \hat{l}^2 2-adrenoceptor overexpressing mice with and without pressure overload. European Journal of Heart Failure, 2003, 5, 131-136.	2.9	15

#	Article	IF	Citations
127	Assessment of Cardiac Function by Echocardiography in Conscious and Anesthetized Mice. Journal of Cardiovascular Pharmacology, 2003, 42, 182-190.	0.8	42
128	Acute Electrophysiologic Effects of Intravenous Amiodarone Are Independent of a Sympatholytic Action in Humans. Journal of Cardiovascular Pharmacology, 2003, 41, 760-765.	0.8	1
129	Sex Hormones and Cardiomyopathic Phenotype Induced by Cardiac \hat{I}^2 2-Adrenergic Receptor Overexpression. Endocrinology, 2003, 144, 4097-4105.	1.4	73
130	Gender Differences in Large Artery Stiffness Pre- and Post Puberty. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5375-5380.	1.8	154
131	Gender, sex hormones and autonomic nervous control of the cardiovascular system. Cardiovascular Research, 2002, 53, 678-687.	1.8	270
132	Fibrillin-1 Genotype Is Associated With Aortic Stiffness and Disease Severity in Patients With Coronary Artery Disease. Circulation, 2002, 105, 810-815.	1.6	70
133	Lower Risk of Postinfarct Rupture in Mouse Heart Overexpressing \hat{I}^2 2-Adrenergic Receptors: Importance of Collagen Content. Journal of Cardiovascular Pharmacology, 2002, 40, 632-640.	0.8	26
134	Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. Journal of the American College of Cardiology, 2002, 39, 1020-1025.	1.2	290
135	Determinants of coronary artery compliance in subjects with and without angiographic coronary artery disease. Journal of the American College of Cardiology, 2002, 39, 1637-1643.	1.2	60
136	Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. Journal of the American College of Cardiology, 2002, 40, 773-779.	1.2	234
137	Large Artery Stiffness and Baroreflex Function. Circulation, 2002, 105, .	1.6	0
138	Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis, 2001, 155, 245-250.	0.4	78
139	Pulse pressureâ€"a review of mechanisms and clinical relevance. Journal of the American College of Cardiology, 2001, 37, 975-984.	1.2	678
140	Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. American Journal of Hypertension, 2001, 14, 804-810.	1.0	30
141	Women exhibit a greater age-related increase in proximal aortic stiffness than men. Journal of Hypertension, 2001, 19, 2205-2212.	0.3	180
142	Gender differences in the timing of arterial wave reflection beyond differences in body height. Journal of Hypertension, 2001, 19, 2197-2203.	0.3	153
143	Cardiac Output In Mice Overexpressing beta2-Adrenoceptors Or With Myocardial Infarct. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 364-370.	0.9	12
144	Large Artery Stiffness: Structural And Genetic Aspects. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1040-1043.	0.9	40

#	Article	IF	Citations
145	Aerobic Exercise Training Does Not Modify Large-Artery Compliance in Isolated Systolic Hypertension. Hypertension, 2001, 38, 222-226.	1.3	152
146	Low-Dose Estrogen Supplementation Improves Vascular Function in Hypogonadal Men. Hypertension, 2001, 38, 1011-1016.	1.3	41
147	Carotid Pressure Is a Better Predictor of Coronary Artery Disease Severity Than Brachial Pressure. Hypertension, 2001, 38, 927-931.	1.3	175
148	Diurnal Variation in Endothelium-Dependent Vasodilatation Is Not Apparent in Coronary Artery Disease. Circulation, 2001, 103, 806-812.	1.6	83
149	Kinins in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 278, R897-R904.	0.9	52
150	Preserved ventricular contractility in infarcted mouse heart overexpressing \hat{l}^2 sub>2 /sub>-adrenergic receptors. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H2456-H2463.	1.5	31
151	\hat{l}^2 ₂ -Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis. Circulation, 2000, 101, 71-77.	1.6	130
152	Exercise and Endothelial Function. Circulation, 2000, 102, E179.	1.6	6
153	Lipids and the endothelium. Cardiovascular Research, 1999, 43, 308-322.	1.8	108
154	Independent Effects of Apo E Phenotype and Plasma Triglyceride on Lipoprotein Particle Sizes in the Fasting and Postprandial States. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2465-2473.	1.1	21
155	Exercise Training Increases Basal Nitric Oxide Production From the Forearm in Hypercholesterolemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2782-2787.	1.1	111
156	EFFECTS OF HEART RATE ON ARTERIAL COMPLIANCE IN MEN. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 342-346.	0.9	60
157	LEFT VENTRICULAR MASS AND MICROALBUMINURIA: RELATION TO AMBULATORY BLOOD PRESSURE. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 514-516.	0.9	17
158	Targets in hypertension. Going nowhere or gone as far as we can go?. Australian and New Zealand Journal of Medicine, 1999, 29, 189-196.	0.5	1
159	Muscular Strength Training Is Associated With Low Arterial Compliance and High Pulse Pressure. Hypertension, 1999, 33, 1385-1391.	1.3	211
160	Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. Journal of the American College of Cardiology, 1999, 33, 805-812.	1.2	127
161	Antiadrenergic effect of chronic amiodarone therapy in human heart failure. Journal of the American College of Cardiology, 1999, 33, 1553-1559.	1.2	34
162	Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. Journal of Hypertension, 1999, 17, 413-418.	0.3	66

#	Article	IF	CITATIONS
163	Higher Systemic Arterial Compliance Is Associated with Greater Exercise Time and Lower Blood Pressure in a Young Older Population. Journal of the American Geriatrics Society, 1999, 47, 653-656.	1.3	45
164	Role of sympathoadrenergic mechanisms in arrhythmogenesis. Cardiovascular Research, 1999, 43, 832-834.	1.8	15
165	Presynaptic Antisympathetic Action of Amiodarone and Its Metabolite Desethylamiodarone. Journal of Cardiovascular Pharmacology, 1999, 33, 309-315.	0.8	3
166	Endothelial Dysfunction Associated with Cardiovascular Disease and Transplantation., 1999,, 417-440.		3
167	Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. British Journal of Pharmacology, 1998, 124, 222-228.	2.7	21
168	Differential Effect of Acute Baroreceptor Unloading on Cardiac and Systemic Sympathetic Tone in Congestive Heart Failure. Journal of the American College of Cardiology, 1998, 31, 583-587.	1.2	59
169	Use of radial artery applanation tonometry and a generalized transfer function to determine aortic pressure augmentation in subjects with treated hypertension. Journal of the American College of Cardiology, 1998, 32, 1214-1220.	1.2	163
170	Relationships between protein C, protein S, von Willebrand factor and euglobulin lysis time and cardiovascular risk factors in subjects with and without coronary heart disease. Atherosclerosis, 1998, 140, 55-64.	0.4	16
171	Age-Related Deterioration in Arterial Structure and Function in Postmenopausal Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1149-1156.	1.1	133
172	Relation Between Coronary Artery Disease, Aortic Stiffness, and Left Ventricular Structure in a Population Sample. Hypertension, 1998, 32, 575-578.	1.3	148
173	The effects of voluntary running on cardiac mass and aortic compliance in Wistar–Kyoto and spontaneously hypertensive rats. Journal of Hypertension, 1998, 16, 181-185.	0.3	35
174	Control of the forearm microcirculation: interactions with measures of obesity and noradrenaline kinetics. Clinical Science, 1998, 95, 203-212.	1.8	22
175	Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size. Clinical Science, 1998, 95, 669-679.	1.8	214
176	Control of the forearm microcirculation: interactions with measures of obesity and noradrenaline kinetics. Clinical Science, 1998, 95, 203.	1.8	12
177	Depression of Efferent Parasympathetic Control of Heart Rate in Rats with Myocardial Infarction: Effect of Losartan. Journal of Cardiovascular Pharmacology, 1998, 31, 937-944.	0.8	32
178	Protection of Neuronal Uptake-1 Inhibitors in Ischemic and Anoxic Hearts by Norepinephrine-Dependent and Independent Mechanisms. Journal of Cardiovascular Pharmacology, 1998, 32, 621-628.	0.8	19
179	Reduced Systemic Arterial Compliance Is Associated with Left Ventricular Hypertrophy and Diastolic Dysfunction in Older People. Journal of the American Geriatrics Society, 1997, 45, 803-808.	1.3	43
180	Risk factors for coronary heart disease in a population with a high prevalence of obesity and diabetes: a case-control study of the Polynesian population of Western Samoa. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 173-178.	1.5	12

#	Article	IF	Citations
181	Spontaneous running increases aortic compliance in Wistar-Kyoto rats. Cardiovascular Research, 1997, 35, 132-137.	1.8	65
182	Hormonal Therapy Increases Arterial Compliance in Postmenopausal Women. Journal of the American College of Cardiology, 1997, 30, 350-356.	1.2	252
183	Arterial compliance increases after moderate-intensity cycling. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H2186-H2191.	1.5	175
184	Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovascular Research, 1997, 34, 590-596.	1.8	19
185	Soy Isoflavones Improve Systemic Arterial Compliance but Not Plasma Lipids in Menopausal and Perimenopausal Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3392-3398.	1.1	414
186	Inhibition of Phosphatidylinositol-Specific Phospholipase C (PLC). Expert Opinion on Therapeutic Targets, 1997, 1, 129-132.	1.0	0
187	EFFECTS OF OESTROGEN AND PROGESTERONE ON AGE-RELATED CHANGES IN ARTERIES OF POSTMENOPAUSAL WOMEN. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 457-459.	0.9	49
188	EFFECTS OF INTRACELLULAR Ca2+CHELATING ON NORADRENALINE RELEASE IN NORMOXIC AND ANOXIC HEARTS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 819-823.	0.9	3
189	A self-administered questionnaire for detection of unrecognised coronary heart disease. Australian and New Zealand Journal of Public Health, 1997, 21, 545-547.	0.8	6
190	A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. American Journal of Cardiology, 1997, 80, 39-44.	0.7	205
191	Arterial Compliance in Obese Subjects Is Improved With Dietary Plant n-3 Fatty Acid From Flaxseed Oil Despite Increased LDL Oxidizability. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1163-1170.	1.1	150
192	Role of Ca 2+ in Metabolic Inhibition–Induced Norepinephrine Release in Rat Brain Synaptosomes. Circulation Research, 1997, 80, 179-188.	2.0	12
193	Protein S, von Willebrand Factor, and Euglobulin Lysis Time as Markers of Coronary Heart Disease. Annals of Internal Medicine, 1997, 126, 89.	2.0	1
194	Pulse wave velocity as a marker of vascular disease. Lancet, The, 1996, 348, 1586-1587.	6.3	8
195	LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers. Atherosclerosis, 1996, 126, 277-287.	0.4	25
196	Systemic arterial compliance is decreased in newly-diagnosed patients with coronary heart disease: implications for prediction of risk. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 495-500.	1.5	39
197	Arrhythmogenic Action of Thrombin During Myocardial Reperfusion via Release of Inositol 1,4,5-Triphosphate. Circulation, 1996, 93, 23-26.	1.6	54
198	The relationship between arterial compliance, age, blood pressure and serum lipid levels. Journal of Hypertension, 1995, 13, 1718???1723.	0.3	52

#	Article	IF	CITATIONS
199	HOW DO FISH OILS AFFECT VASCULAR FUNCTION?. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 71-81.	0.9	63
200	Determinants of arterial stiffness in Chinese migrants to Australia. Atherosclerosis, 1995, 117, 263-272.	0.4	29
201	Suppression of Ventricular Arrhythmias During Ischemia-Reperfusion by Agents Inhibiting Ins(1,4,5)P ₃ Release. Circulation, 1995, 91, 2712-2716.	1.6	68
202	Sympatholytic Action of Intravenous Amiodarone in the Rat Heart. Circulation, 1995, 91, 462-470.	1.6	61
203	Inositol Phosphate Release and Metabolism During Myocardial Ischemia and Reperfusion in Rat Heart. Circulation Research, 1995, 76, 261-268.	2.0	59
204	THERAPEUTIC RESTORATION OF ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLAEMIC SUBJECTS: EFFECT OF FISH OILS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 749-755.	0.9	49
205	LOW CHOLESTEROL AND IMPAIRED CARDIAC FUNCTION FOLLOWING HEART TRANSPLANTATION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 659-661.	0.9	0
206	Effects of dietary marine oil supplementation on reactivity of human buttock subcutaneous arteries and forearm veins <i>in vitro</i> . British Journal of Pharmacology, 1994, 112, 566-570.	2.7	11
207	Inhibition of prostaglandin synthesis does not affect contractile responses to noradrenaline, serotonin, angiotensin II nor endothelin†in human forearm isolated veins. British Journal of Clinical Pharmacology, 1993, 36, 303-307.	1.1	0
208	Sympathetic Activation and Increased Extracellular Potassium. Journal of Cardiovascular Pharmacology, 1993, 21, 977-982.	0.8	6
209	Mechanisms of noradrenaline release in the anoxic heart of the rat. Cardiovascular Research, 1993, 27, 2011-2015.	1.8	11
210	Indomethacin inhibits the effects of dietary supplementation with marine oils on vasoconstriction of human forearm resistance vessels in vivo. Journal of Hypertension, 1993, 11, 1229???1234.	0.3	21
211	Exercise training reduces the sympathetic component of the blood pressure-heart rate baroreflex in man. Clinical Science, 1992, 82, 357-362.	1.8	57
212	EFFECTS OF 4 WEEKS ENDURANCE TRAINING ON CARDIAC LEFT VENTRICULAR STRUCTURE AND FUNCTION. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 777-783.	0.9	15
213	Is adrenaline released by sympathetic nerves in man?. Clinical Autonomic Research, 1991, 1, 103-108.	1.4	29
214	ADRENALINE RELEASE BY THE HUMAN HEART. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 67-70.	0.9	9
215	Effects of Exercise and Other Nonpharmacological Measures on Blood Pressure and Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 1991, 17, S70-S74.	0.8	20
216	A novel effect of pargyline on cholinergic catecholamine secretion. Biochemical Pharmacology, 1989, 38, 1699-1702.	2.0	1

ANTHONY M DART

#	Article	lF	CITATIONS
217	Neurally Mediated and Spontaneous Release of Noradrenaline in the Ischemic and Reperfused Rat Heart. Journal of Cardiovascular Pharmacology, 1985, 7, S45-S49.	0.8	13
218	Paradoxical Role of Neuronal Uptake for the Locally Mediated Release of Endogenous Noradrenaline in the Ischemic Myocardium. Journal of Cardiovascular Pharmacology, 1985, 7, S40-S44.	0.8	27